Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Complement Control Protein

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    26 result(s) found for: Complement Control Protein. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2020-000086-17 Sponsor Protocol Number: AK901 Start Date*: 2020-08-06
    Sponsor Name:Akari Therapeutics Plc
    Full Title: Multicentre Study of nomacopan in Paediatric Haematopoietic Stem-Cell Transplant Associated Thrombotic Microangiopathy
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043645 Thrombotic microangiopathy PT
    21.1 10042613 - Surgical and medical procedures 10063581 Stem cell transplant PT
    22.0 10042613 - Surgical and medical procedures 10067859 Allogenic stem cell transplantation PT
    22.0 10042613 - Surgical and medical procedures 10081347 Autologous haematopoietic stem cell transplant PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004486-40 Sponsor Protocol Number: R3918-PNH-2021 Start Date*: 2022-04-04
    Sponsor Name:REGENERON PHARMACEUTICALS, INC.
    Full Title: A RANDOMIZED, OPEN-LABEL, RAVULIZUMAB-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO A...
    Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) ES (Ongoing) PL (Ongoing) GR (Ongoing) HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001586-87 Sponsor Protocol Number: RSLV-132-04 Start Date*: 2016-09-29
    Sponsor Name:Resolve Therapeutics, LLC
    Full Title: A Phase 2, Double Blind, Placebo Controlled Study of RSLV-132 in Subjects with Primary Sjogren’s Syndrome
    Medical condition: Primary Sjogrens Syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-004367-20 Sponsor Protocol Number: MET54 Start Date*: 2015-03-16
    Sponsor Name:Sanofi Pasteur
    Full Title: A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccines in Healthy Toddlers
    Medical condition: Healthy volunteers (active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y or W)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10058858 Meningococcal bacteraemia PT
    18.0 10021881 - Infections and infestations 10027274 Meningococcal infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2014-001372-66 Sponsor Protocol Number: TACmono-100 Start Date*: 2014-07-16
    Sponsor Name:Erasmus Medical Center
    Full Title: Tacrolimus monotherapy in immunologically low-risk kidney transplant recipients: a pilot randomized-controlled study.
    Medical condition: kidney transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-004931-10 Sponsor Protocol Number: R3918-PNH-2050 Start Date*: 2022-12-27
    Sponsor Name:REGENERON PHARMACEUTICALS, INC.
    Full Title: An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria
    Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) PL (Ongoing) GR (Ongoing) HU (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002718-38 Sponsor Protocol Number: 111670 Start Date*: 2015-06-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, open, controlled, multi-center study to evaluate the long-term antibody persistence at 1 year, 3 years and 5 years after the administration of one dose of GlaxoSmithKline (GSK) Biologic...
    Medical condition: Invasive disease caused by Neisseria meningitidis serogroups A, C W-135 and Y
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10028910 Neisseria meningitides meningitis LLT
    18.0 100000004862 10051931 Neisseria infection NOS LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-023873-20 Sponsor Protocol Number: B1971009(6108A1-3001) Start Date*: 2011-11-08
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED TRIAL TO ASSESS THE LOT CONSISTENCY, SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MENINGOCOCCAL SEROGROUP B BIVALENT RLP2086 VACCINE IN H...
    Medical condition: BACTERIAL MENINGITIS.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10004049 Bacterial meningitis LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) FI (Completed) CZ (Completed) GB (Completed) ES (Completed) PL (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-001923-11 Sponsor Protocol Number: Nef-202 Start Date*: 2012-10-17
    Sponsor Name:Pharmalink AB
    Full Title: A Multicentre, Interventional Treatment, Randomised, Double-Blind, Single Group Assignment, Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon® in Primar...
    Medical condition: Primary IgA nephropathy patients at risk of developing end stage renal disease
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004857 10069341 Berger's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) CZ (Completed) DE (Completed) BE (Completed) SE (Completed) DK (Completed) IT (Completed) GB (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-004734-25 Sponsor Protocol Number: V72P3 Start Date*: 2014-11-11
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase 2, Single-Blind, Controlled, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine OMV When Administered at an 0-2-6-Month Schedul...
    Medical condition: Prophylaxis Aganist Invasive Meningococcal Disease
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-006013-34 Sponsor Protocol Number: 115884 Start Date*: 2013-01-11
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open, controlled, multi-centric study to evaluate the immunogenicity, safety and reactogenicity of GSK Biologicals' 10-valent pneumococcal conjugate vaccine when administered to childr...
    Medical condition: Active immunization against disease caused by Streptococcus pneumoniae in children 2-17 years of age who are at increased risk of pneumococcal infection.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10042197 Streptococcus pneumoniae septicaemia LLT
    14.1 100000004862 10042195 Streptococcus pneumoniae pneumonia LLT
    14.1 100000004862 10054642 Streptococcus pneumoniae septicemia LLT
    15.1 100000004862 10035648 Pneumococcal pneumonia [Streptococcus pneumoniae pneumonia] LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-006028-41 Sponsor Protocol Number: BER-PUM-01 Start Date*: 2022-02-21
    Sponsor Name:Pomorski Uniwersytet Medyczny w Szczecinie
    Full Title: Evaluation of the safety and efficacy of Berubicin in the treatment of central nervous system lymphomas- BERUBICIN
    Medical condition: Primary central nervous system lymphoma (PCNSL) and secondary non-Hodgkin's lymphoma with central nervous system involvement (NHL-CNSI)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003157-27 Sponsor Protocol Number: Sobi.PEGCET-201 Start Date*: 2021-12-17
    Sponsor Name:SWEDISH ORPHAN BIOVITRUM AB (PUBL)
    Full Title: An Open-label, Single-arm, Multicenter Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Pegcetacoplan in Patients with Transplant-associated Thrombotic Microangiopathy (...
    Medical condition: Transplant-Associated Thrombotic Microangiopathy (TA-TMA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043645 Thrombotic microangiopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) GR (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002410-36 Sponsor Protocol Number: 115524 Start Date*: 2012-07-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open, controlled study to evaluate immunogenicity of GSK Biologicals’ MenACWY-TT conjugate vaccine administered intramuscularly to at risk subjects from 1 to less than 18 years and to ...
    Medical condition: Meningococcal infection
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004862 10027275 Meningococcal infection, unspecified LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-002719-24 Sponsor Protocol Number: 112021 Start Date*: 2015-06-01
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, open, multi-center study to evaluate the long-term anti-body persistence at 1 year, 3 years and 5 years after the administration of one or two doses of GlaxoSmithKline (GSK) Biologicals...
    Medical condition: Invasive disease caused by Neisseria meningitidis serogroups A, C W-135 and Y
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10028910 Neisseria meningitides meningitis LLT
    18.0 100000004862 10028911 Neisseria meningitidis infection NOS LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-002431-30 Sponsor Protocol Number: GT005-03 Start Date*: 2020-10-21
    Sponsor Name:Gyroscope Therapeutics
    Full Title: HORIZON: A Phase II, open-label, outcomes-assessor masked, multicentre, randomised,controlled study to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal inj...
    Medical condition: Age-related Macular Degeneration (AMD) presents as a progressive loss of vision in the centre of the retina (the macula) resulting in a blurred area or blank spot in the centre of vision. The prima...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10075719 Atrophic age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) FR (Completed) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014492-46 Sponsor Protocol Number: B1971016(6108A1-2004) Start Date*: 2011-05-19
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED, TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BIVALENT rLP2086 VACCINE WHEN ADMINISTERED AS A 3-DOSE REGIMEN IN HEALTH...
    Medical condition: Pfizer‘s investigational bivalent rLP2086 vaccine is being developed for prevention of invasive meningococcal disease caused by N meningitidis serogroup B.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10028911 Neisseria meningitidis infection NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) PL (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-000417-31 Sponsor Protocol Number: IM101-473 Start Date*: 2014-07-01
    Sponsor Name:University Medical Center Groningen
    Full Title: Randomized, double-blind, placebo-controlled phase III study (ASAP III study) to assess the efficacy and safety of Abatacept treatment in patients with primary Sjögren’s syndrome (ASAP III study = ...
    Medical condition: Primary Sjögren's syndrome (pSS)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004859 10042846 Syndrome Sjogren's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001693-33 Sponsor Protocol Number: ITL-2002-CL-001 Start Date*: 2022-03-30
    Sponsor Name:Intellia Therapeutics, Inc.
    Full Title: Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults with Hereditary Angioedema (HAE)
    Medical condition: Hereditary Angioedema
    Disease: Version SOC Term Classification Code Term Level
    23.1 10010331 - Congenital, familial and genetic disorders 10019860 Hereditary angioedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) FR (Trial now transitioned) DE (Trial now transitioned) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003781-40 Sponsor Protocol Number: GCT3014-01 Start Date*: 2021-01-11
    Sponsor Name:Genmab A/S
    Full Title: An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
    Medical condition: Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066481 Hematological malignancy LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing) ES (Ongoing) FR (Ongoing) NL (Ongoing) HU (Ongoing) CZ (Ongoing) PL (Ongoing) GR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:41:44 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA